Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood. - Wikidata - thesis-toulmin - TriplyDB

Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.

Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.

http://www.wikidata.org/entity/Q50665953

about

The Role of the Transcriptional Regulation of Stromal Cells in Chronic Inflammation Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer Regulation and function of TPL-2, an IκB kinase-regulated MAP kinase kinase kinase The protein kinase TPL2 is essential for ERK1/ERK2 activation and cytokine gene expression in airway epithelial cells exposed to pathogen-associated molecular patterns (PAMPs)Tumor progression locus 2 (Tpl2) kinase promotes chemokine receptor expression and macrophage migration during acute inflammation.Data driven linear algebraic methods for analysis of molecular pathways: application to disease progression in shock/trauma.Tumor progression locus 2 (Map3k8) is critical for host defense against Listeria monocytogenes and IL-1 beta production.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.Pharmacological inhibition of TPL2/MAP3K8 blocks human cytotoxic T lymphocyte effector functions.Tumor progression locus 2 differentially regulates IFNγ and IL-17 production by effector CD4+ T cells in a T cell transfer model of colitis Basolateral LPS inhibits NHE3 and HCOFormula absorption through TLR4/MyD88-dependent ERK activation in medullary thick ascending limb Genetic and pharmacologic inhibition of Tpl2 kinase is protective in a mouse model of ventilator-induced lung injury.Tumoricidal Effects of Macrophage-Activating Immunotherapy in a Murine Model of Relapsed/Refractory Multiple Myeloma All-trans retinoic acid suppresses interleukin-6 expression in interleukin-1-stimulated synovial fibroblasts by inhibition of ERK1/2 pathway independently of RAR activation TPL-2 negatively regulates interferon-beta production in macrophages and myeloid dendritic cells.Electrochemiluminescence in bioanalysis.IκB kinase regulation of the TPL-2/ERK MAPK pathway.Mitogen-activated protein kinases as therapeutic targets for rheumatoid arthritis.Tpl2 promotes innate cell recruitment and effector T cell differentiation to limit Citrobacter rodentium burden and dissemination.Novel cross-talk within the IKK family controls innate immunity.IRAK1-independent pathways required for the interleukin-1-stimulated activation of the Tpl2 catalytic subunit and its dissociation from ABIN2.Severe Dermatitis Associated with Spontaneous Staphylococcus xylosus Infection in Rag-/-Tpl2-/- Mice.Tpl2 promotes neutrophil trafficking, oxidative burst, and bacterial killing.Tumor Progression Locus 2 (Tpl2) Activates the Mammalian Target of Rapamycin (mTOR) Pathway, Inhibits Forkhead Box P3 (FoxP3) Expression, and Limits Regulatory T Cell (Treg) Immunosuppressive Functions.A multitude of kinases--which are the best targets in treating rheumatoid arthritis?Tpl2 regulates intestinal myofibroblast HGF release to suppress colitis-associated tumorigenesis.Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation.Stimulation of TLR4 by recombinant HSP70 requires structural integrity of the HSP70 protein itself.A TPL2 (MAP3K8) disease-risk polymorphism increases TPL2 expression thereby leading to increased pattern recognition receptor-initiated caspase-1 and caspase-8 activation, signalling and cytokine secretion.Assaying kinase activity of the TPL-2/NF-κB1 p105/ABIN-2 complex using an optimal peptide substrate.Involvement of Cot/Tp12 in bone loss during periodontitis.Genetic and pharmacological targeting of TPL-2 kinase ameliorates experimental colitis: a potential target for the treatment of Crohn's disease?Suppressive effect of an orally active MEK1/2 inhibitor in two different animal models for rheumatoid arthritis: a comparison with leflunomide.Pharmacophore generation and atom-based 3D-QSAR of novel quinoline-3-carbonitrile derivatives as Tpl2 kinase inhibitors.

P2860

Q26778930-AC4006D4-7184-4F2C-9690-4E238390D8DF Q27021391-22BBE3C5-E226-4699-BF86-3F77B8A2C4D9 Q28392677-064DDE2D-D125-445F-BE29-747BEC9D2018 Q28488321-3C615E59-1C75-4C94-AFAC-890197FBE471 Q34076041-D64A280E-6677-4F8D-BEE6-D9691978F72B Q34112355-F31D725E-7147-4911-B92A-8C793849A583 Q34157182-59ECC57A-1020-46BA-B86E-D0DF5312DCAB Q34329242-3C20068B-1D33-4137-80D9-3373F0ADAF34 Q35124167-BB00D1D4-231E-4CCA-82BE-D8AD24F70708 Q35187958-2D41F201-7EBB-4EAB-B45A-51E3E9E14040 Q35601331-29C394D3-46A5-4483-AECF-52236B545352 Q35883560-5D935E0E-4573-4BC2-9034-AEBD7B9D374A Q35925252-543F2C8D-83A6-4081-B2BE-4CCA0206E5C0 Q37129596-BAE9A535-9192-437C-9E01-8678A3D47EFF Q37331514-64A4E24D-F0E9-4C6B-9178-B36BBCFE0039 Q37810142-B9EA9D21-02BA-4863-946F-CC5DD0C835C7 Q37995683-4A372D1A-C038-4726-B194-319A463BC594 Q38078271-D14E0E56-DB04-4168-B2C7-3EF723556950 Q38650821-15B23D0B-FB21-4EEC-AADD-3B26E9DA606E Q39622962-AF6AF1FA-1119-4539-95DC-181FDE62A75D Q39799629-BFE27BBF-B3C9-444D-9493-E171168A24E9 Q40083976-047E5A43-FD12-436D-BB74-5F1535232756 Q40273190-8D0937AA-29A9-4D31-AE87-784F6E6B295A Q40645815-565549BA-7FA2-47E7-9CE3-43A8B6F25724 Q40840109-E5F7BF0D-4E56-463C-AE85-2847484DB0F9 Q41626594-4BFA7947-EE12-4BB1-8010-1FEFAEEB3981 Q42103739-CE8763D9-0E1D-4FC3-8953-A0AD82283072 Q42174265-6927B821-F233-4FD1-B4D5-1557C43744F6 Q42741761-F2466AAD-2179-4CD6-88F1-7929C546B975 Q49920636-22E3BB1D-A471-4D1A-90B0-6661B7BD84F1 Q51917295-018CFEA1-AFD3-4114-8133-70E5E9417DA3 Q52891216-63122145-BB85-4683-BC03-DC7EECBB1E99 Q54536252-504C12B9-F7F1-47C0-9970-570040E468D7 Q54567103-F3D86EDA-838C-4B3C-9DCE-D836EEF46EB7

P2860

Pharmacologic inhibition of tpl2 blocks inflammatory responses in primary human monocytes, synoviocytes, and blood.

http://www.wikidata.org/entity/Q50665953

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Pharmacologic inhibition of tp ...... ytes, synoviocytes, and blood.

@en

Pharmacologic inhibition of tp ...... ytes, synoviocytes, and blood.

@nl

type

label

Pharmacologic inhibition of tp ...... ytes, synoviocytes, and blood.

@en

Pharmacologic inhibition of tp ...... ytes, synoviocytes, and blood.

@nl

prefLabel

Pharmacologic inhibition of tp ...... ytes, synoviocytes, and blood.

@en

Pharmacologic inhibition of tp ...... ytes, synoviocytes, and blood.

@nl

P1433

Q50665953-2B589D12-9C52-4762-B100-F4D87CAC7BDA

P1476

Q50665953-2BBD0FAB-42A0-428D-981D-9003BABBB0F9

P2093

Q50665953-11F85592-1DF5-4922-8245-E8318B22E2F2

Q50665953-1EC6DD79-2A6B-4300-880C-CC84A25086D6

Q50665953-211E8819-AD55-45D9-B6D6-CD8069DA74A2

Q50665953-26B1694A-05EB-469C-814F-54FBF4440CDC

Q50665953-5DFA62BE-F7BE-46E6-9855-FBD78E436D17

Q50665953-69DDE7FC-BE4F-4426-8B4A-9B12C9441499

Q50665953-7434F279-C5C9-45A9-988C-E90417811358

Q50665953-95F04D26-C774-4001-99C3-75D3F32E9D39

Q50665953-99687540-7B89-4B53-87FC-981EA747A445

Q50665953-B01A945B-17CD-4A4C-B918-54D6AAC1EC1D

P2860

Q50665953-017DA5ED-CFD3-4040-A270-B0768679669C

Q50665953-033E6AA7-AEBF-43E9-965C-7C230861F30C

Q50665953-047138EA-4ACC-4297-B1C1-291B175AF7D4

Q50665953-09CE9005-64C2-433D-AF93-D71AD734B3F1

Q50665953-1254178C-30DA-4DE1-9804-3CEE20D7F389

Q50665953-13978DD5-6266-410E-BDF4-48C93AC19D4C

Q50665953-17CD0CE8-D7E8-4AD8-B704-4595937F23A0

Q50665953-2366B856-1897-43A4-87D8-8744A62952B4

Q50665953-236E33D8-E844-41C9-BDD5-376A18856D7A

Q50665953-2FE36892-890A-464E-B1D6-0E2A37E29F9F

P304

Q50665953-B95E478F-CF4D-4146-89DE-E45DEFCCAB24

P31

Q50665953-279B7C56-DDAA-4BCA-9598-6971EACDE63E

P356

Q50665953-DCFD3FD1-C564-413A-BC59-DD695450B19A

P407

Q50665953-9071E554-6389-48A9-A7D5-CC2D006E70A5

P433

Q50665953-E44ED0C9-8829-4438-A211-66A44806AF4F

P478

Q50665953-878E63B6-FEC3-410A-A21A-A3F3935F68FC

P50

Q50665953-6BBC3836-5F3C-4F30-B991-05DA42A1DBD8

P577

Q50665953-A0B1A3FD-AF3A-4169-8E07-6A9E6A40D867

P698

Q50665953-2F329B71-874C-46D4-9E50-E97A9A9F929D

P921

Q50665953-80987925-87B1-4491-9352-7E1E6BE51AD4

P356

P1433

Journal of Biological Chemistry

P1476

Pharmacologic inhibition of tp ...... cytes, synoviocytes, and blood

@en

P2093

Aaron Winkler

http://www.w3.org/2001/XMLSchema#string

G Roger Askew

http://www.w3.org/2001/XMLSchema#string

J Perry Hall

http://www.w3.org/2001/XMLSchema#string

James D Clark

http://www.w3.org/2001/XMLSchema#string

Jean-Baptiste Telliez

http://www.w3.org/2001/XMLSchema#string

Julie Liu

http://www.w3.org/2001/XMLSchema#string

Katherine J Seidl

http://www.w3.org/2001/XMLSchema#string

Lih-Ling Lin

http://www.w3.org/2001/XMLSchema#string

Neal Green

http://www.w3.org/2001/XMLSchema#string

Sang Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel human kinase supporter of Ras (hKSR-2) that functions as a negative regulator of Cot (Tpl2) signaling

ABIN-2 is required for optimal activation of Erk MAP kinase in innate immune responses

Genetic dissection of the cellular pathways and signaling mechanisms in modeled tumor necrosis factor-induced Crohn's-like inflammatory bowel disease.

TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway.

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

Cytokine pathways and joint inflammation in rheumatoid arthritis.

Cyclooxygenase-1 and -2 expression in rheumatoid synovial tissues. Effects of interleukin-1 beta, phorbol ester, and corticosteroids.

Biology of tumor necrosis factor-alpha- implications for psoriasis.

Tpl-2 acts in concert with Ras and Raf-1 to activate mitogen-activated protein kinase.

Tumor progression locus 2 (Tpl-2) encodes a protein kinase involved in the progression of rodent T-cell lymphomas and in T-cell activation

P304

33295-33304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1074/JBC.M703694200

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

282

http://www.w3.org/2001/XMLSchema#string

P50

P577

2007-09-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17848581

http://www.w3.org/2001/XMLSchema#string

P921